Using Epidemiology Data in HTA Submissions: A Practical Framework
How pharmaceutical companies can structure robust epidemiology evidence packages for health technology assessment bodies in the UK, Germany, France, and beyond.
Read More
Epidemiology forecast models
for strategic decision makers
Evidence-based and fully transparent 
State-of-the-art forecasting approach 
200+ drug indications across 26 high-income countries 
20-year forecast period
Forecasting a rare diseases
without prevalence estimates
Evidence-based and fully transparent
State-of-the-art forecasting approach
200+ drug indications across 26 high-income countries
20-year forecast period
Cancer Populations USA
Take a deep-dive into U.S. cancer epidemiology
Evidence-based and fully transparent
State-of-the-art forecasting approach
200+ drug indications across 26 high-income countries
20-year forecast period
About Epivantage
Epidemiology insights and forecast models
Epivantage specializes in the development of rigorously researched and detailed epidemiological forecast models that are fit for purpose in the age of genetic medicine, targeted treatments and niche drug labels. These models are available on a custom basis or as downloadable files from our Model Library.
Learn more about us
Products and Services
Epidemiology forecast models and insights
Epivantage specializes in the development of rigorously researched and detailed epidemiological forecast models that are fit for purpose in the age of genetic medicine, targeted treatments and niche drug labels. These models are available on a custom basis or as downloadable files from our Model Library.
G26 Epidemiology Forecast
Updateable epidemiology forecast models covering 26 high-income countries. Each forecast population maps onto eligible drug populations, with a 'sandbox' capability to test alternative scenarios.
Learn more
G26 Oncology Forecast
Cancer epidemiology forecast models covering 26 high-income countries, driver mutations and biomarker populations, patient flows through successive lines of treatment.
Learn more
Rare Disease Epidemiology Service
Rare disease forecasting service across select major markets, available from our Model Library, or comissioned as a custom engagement.
Contact us
Case Studies
View cases studies
How our research drives strategic decision-making
Some examples of recent custom engagements demonstrating how our epidemiology models feed into the broader drug development and commercialization process.
01
Estimating the size of the high-risk myelodysplastic syndrome market
34
Forecast populations
20 yrs
Forecast horizon
2
Custom analyses
02
Rare Disease Patient Identification — Global Epidemiology Analysis
03
COPD Pipeline Positioning & Patient Segmentation
6
Markets
11
Studies
2
Variables
04
Recurrent anaphylaxis epidemiology across 5 markets and 12 market access scenarios
5
Markets covered
20 yrs
Forecast horizon
12
Market access scenarios
Why pharmaceutical companies choose Epivantage for their definitive Epidemiology forecasts
The Epivantage leadership team has 20 years experience in developing epidemiology forecast models, and have defined the current gold standard in forecasting methods. Building on this expertise, with a focus on commercially relevant eligible patient populations, it is our founding objective to be unique in terms of the quality and defensibility of our forecast models and commercial alignment with the needs of our clients.
Evidence based epidemiology for modern drug development
Epivantage delivers rigorously researched, evidence based, and flexible epidemiological forecast models that meet the evolving needs of today’s pharmaceutical industry. As genetic medicine, targeted therapies, and niche drug labels reshape modern medicine, our models are designed to provide the clarity and accuracy required for confident decision making.
Forecast populations aligned to real world eligibility
We are committed to ensuring that every forecast population reflects the actual or potential eligible patient population in clinical practice. Our epidemiologists align model outputs with real world criteria, using clinical trial inclusion criteria, approved drug labels, and prevailing treatment guidelines to inform our coverage.
AI-powered TLRs
All our estimates originate from targeted literature reviews (TLRs) and our analyses of real-world datasets. Our TLRs include the results of a dedicated AI agent which are incorporated alongside the manual TLR results and the results returned from our proprietary inhouse data catalogs.
Industry Perspectives & Healthcare Research Updates
Visit Industry InsightEmerging Trends in Oncology Epidemiology: What Pharma Strategists Need to Know
Key epidemiological shifts in the oncology landscape — including improving survival rates, expanding screening programmes, and changing incidence patterns — and their implications for pipeline strategy.
Read MoreUnderstanding Epidemiology Forecast Modelling: Principles and Best Practices
A comprehensive guide to the foundational principles of age-period-cohort modelling and how Epivantage applies validated epidemiological frameworks to generate decision-ready forecast models. In this article: Forecasting methodology principles
Read More